Ubambiswano lwe-ADNAB kunye neKliniki yaseMayo1
Iqonga lomnini wesizukulwana esilandelayo se-ADC
Ngokusekwe kumsebenzi kaSvetomir Markovic kunye noogxa baseMayo Clinic2,3
Ivumela ukubophelela kwezilwa-buhlungu kumthwalo wamachiza kwi-oncology nangaphaya
Ijikeleze imfuno yokuba:
- Ukusetyenziswa kwetekhnoloji ye-covalent "linker".
- Ukufakwa ngaphakathi kwiseli
Kwaziwa, izilwa-buhlungu ezisebenzayo ngokweklinikhi zi non-covalently ubopheleleke kwimithwalo yeziyobisi ngokwakhiwa komxube onelungelo elilodwa lomenzi wechiza
- Enye okanye ezininzi izilwa-ntsholongwane ezisebenza ngonyango okanye ezikhuselayo
- "Isuntswana" le-albumin
- Umvuzo weziyobisi
Umphandi uqalise ubungqina bemiqondo yezifundo eziqhubekayo kwi-B cell lymphoma, melanoma, kunye nomhlaza wesibeleko.
Ipotfoliyo yepropathi enomgangatho ophezulu wokuqonda iqulathe iintsapho ezili-17 zamalungelo awodwa omenzi wechiza, amalungelo awodwa omenzi wechiza angama-32 anikezelweyo ukuza kuthi ga ngoku ngo-2035 kwaye amanye ayi-135 axhonyiweyo.
1) Ngo-2020, i-Sorrento yafumana ilayisensi ekhethekileyo yokuphuhlisa kunye nokuthengisa i-ADNAB ngokubambisana neMayo Clinic.
2) Nevala W, et al. I-antibody-target chemotherapy kunyango lwe-melanoma. Umhlaza Res. 2016; 76:3954-3964. 2
3) Butterfield JT, et al. Ukuchongwa kwe-peptide-peptide ebophelelayo i-motif kwi-coating ye-nab-paclitaxel nanoparticles enee-antibodies zeklinikhi: i-bevacizumab, i-rituximab, kunye ne-trastuzumab. Sci Rep. 2017; 7:14476.